Busari Zulaikha A, Dauda Kabiru A, Morenikeji Olajumoke A, Afolayan Funmilayo, Oyeyemi Oyetunde T, Meena Jairam, Sahu Debasis, Panda Amulya K
Department of Zoology, University of IbadanIbadan, Nigeria.
Department of Biological Sciences, University of Medical SciencesOndo, Nigeria.
Front Pharmacol. 2017 Sep 6;8:622. doi: 10.3389/fphar.2017.00622. eCollection 2017.
Curcumin is a polyphenolic pigment isolated from the rhizomes of (turmeric), a medicinal plant widely used in the ancient Indian and Chinese medicine. The antiplasmodial activity of curcumin is often hampered by its fast metabolism and poor water solubility, thus its incorporation into a delivery system could circumvent this problem. This study aimed to evaluate the antiplasmodial activity and the toxicity assessment of curcumin incorporated into poly (lactic-co-glycolic) acid (PLGA) nanoparticles. Curcumin was loaded with poly (D,L-lactic-co-glycolic acid) (PLGA) using solvent evaporation from oil-in-water single emulsion method. The nanoparticles were characterized and evaluated for antimalarial activities using Peter's 4-day suppressive protocol in mice model. Hematological and hepatic toxicity assays were performed on whole blood and plasma, respectively. anti-parasitic test and toxicity assays for free and encapsulated drug were performed at 5 and 10 mg/kg. cytotoxicity of free and PLGA encapsulated curcumin (Cur-PLGA) to RAW 264.7 cell line was also determined at varying concentrations (1000-7.8 μg/mL). The size and entrapment efficiency of the nanoparticulate drug formulated was 291.2 ± 82.1 nm and 21.8 ± 0.4 respectively. The percentage parasite suppression (56.8%) at 5 mg/kg was significantly higher than in free drug (40.5%) of similar concentration ( < 0.05) but not at 10 mg/kg (49.5%) at 4-day post-treatment. There were no significant differences in most of the recorded blood parameters in free curcumin and PLGA encapsulated nanoparticulate form ( > 0.05) except in lymphocytes which were significantly higher in Cur-PLGA compared to the free drug ( < 0.05). There were no significant differences in hepatotoxic biomarkers; aspartate aminotransferase and alanine aminotransferase concentrations in various treatment groups ( > 0.05). At higher concentrations (1000 and 500 μg/mL), Cur-PLGA entrapped nanoparticle showed higher toxicity compared with the free drug ( < 0.05) in exposed RAW 264.7 cell line. The cell viability was, however, higher in Cur-PLGA nanoparticles than in free curcumin at lower concentrations ( > 0.05). The antiplasmodial activity and safety of Cur-PLGA was better at lower concentration.
姜黄素是从姜黄根茎中分离出的一种多酚类色素,姜黄是一种在古印度和中国医学中广泛使用的药用植物。姜黄素的抗疟活性常常因其快速代谢和较差的水溶性而受到阻碍,因此将其纳入递送系统可以规避这一问题。本研究旨在评估负载于聚(乳酸-乙醇酸)共聚物(PLGA)纳米颗粒中的姜黄素的抗疟活性和毒性评估。采用水包油单乳液法通过溶剂蒸发将姜黄素负载到聚(D,L-乳酸-乙醇酸)共聚物(PLGA)中。使用小鼠模型中的彼得4天抑制方案对纳米颗粒进行表征并评估其抗疟活性。分别对全血和血浆进行血液学和肝毒性测定。游离药物和包封药物的抗寄生虫试验和毒性测定在5和10 mg/kg剂量下进行。还在不同浓度(1000-7.8 μg/mL)下测定了游离姜黄素和PLGA包封的姜黄素(Cur-PLGA)对RAW 264.7细胞系的细胞毒性。所制备的纳米颗粒药物的粒径和包封率分别为291.2±82.1 nm和21.8±0.4。在治疗后4天,5 mg/kg剂量下的寄生虫抑制率(56.8%)显著高于相似浓度的游离药物(40.5%)(P<0.05),但10 mg/kg剂量下(49.5%)无显著差异。除淋巴细胞外,游离姜黄素和PLGA包封的纳米颗粒形式的大多数记录血液参数无显著差异(P>0.05),其中Cur-PLGA中的淋巴细胞显著高于游离药物(P<0.05)。各治疗组的肝毒性生物标志物天冬氨酸转氨酶和丙氨酸转氨酶浓度无显著差异(P>0.05)。在较高浓度(1000和500 μg/mL)下,Cur-PLGA包封的纳米颗粒在暴露的RAW 264.7细胞系中显示出比游离药物更高的毒性(P<0.05)。然而,在较低浓度下(P>0.05),Cur-PLGA纳米颗粒中的细胞活力高于游离姜黄素。较低浓度下Cur-PLGA的抗疟活性和安全性更好。